ImmunoGen Company Profile (NASDAQ:IMGN)

About ImmunoGen (NASDAQ:IMGN)

ImmunoGen logoImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IMGN
  • CUSIP: 45253H10
  • Web:
  • Market Cap: $553.06 million
  • Outstanding Shares: 89,348,000
Average Prices:
  • 50 Day Moving Avg: $6.00
  • 200 Day Moving Avg: $4.11
  • 52 Week Range: $1.51 - $8.04
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.15
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $51.8 million
  • Price / Sales: 10.68
  • Book Value: ($1.88) per share
  • Price / Book: -3.29
  • EBIDTA: ($104,780,000.00)
  • Net Margins: -244.76%
  • Return on Assets: -60.22%
  • Debt-to-Equity Ratio: -0.58%
  • Current Ratio: 3.52%
  • Quick Ratio: 3.44%
  • Average Volume: 2.77 million shs.
  • Beta: 2.45
  • Short Ratio: 5.27
Frequently Asked Questions for ImmunoGen (NASDAQ:IMGN)

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) released its quarterly earnings data on Friday, May, 5th. The company reported ($0.20) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.36) by $0.16. The firm had revenue of $28.70 million for the quarter, compared to the consensus estimate of $16.16 million. The company's revenue was up 45.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.37) EPS. View ImmunoGen's Earnings History.

Where is ImmunoGen's stock going? Where will ImmunoGen's stock price be in 2017?

9 brokerages have issued 1 year price objectives for ImmunoGen's stock. Their predictions range from $1.30 to $12.00. On average, they anticipate ImmunoGen's stock price to reach $6.61 in the next year. View Analyst Ratings for ImmunoGen.

What are analysts saying about ImmunoGen stock?

Here are some recent quotes from research analysts about ImmunoGen stock:

  • 1. According to Zacks Investment Research, "ImmunoGen has made significant progress with regard to its lead pipeline candidate, mirvetuximab soravtansine (platinum-resistant ovarian cancer). However, most of the pipeline candidates are in early stages of development and still a long way from entering the market, if at all. Moreover, ImmunoGen has only a limited number of wholly owned candidates in its pipeline. Hence successful development and subsequent approval of its lead candidate, is crucial for growth at ImmunoGen. On the flip side, the company’s collaborations with big healthcare companies not only validate its technology but also provide it with funds in the form of milestone and royalty payments. The company’s shares have outperformed the broader industry so far this year. Notably, estimates have been going down lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/10/2017)
  • 2. Cantor Fitzgerald analysts commented, "IMGN’s announced sale of IMGN529 to Debiopharm for an aggregate of $55 mln provides incremental cash to the company for development of." (5/24/2017)
  • 3. Cowen and Company analysts commented, "IMGN presented data from mrive’s Phase I biopsy expansion cohort at SGO." (3/13/2017)

Who are some of ImmunoGen's key competitors?

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the folowing people:

  • Stephen C. McCluski, Independent Chairman of the Board
  • Mark J. Enyedy, President, Chief Executive Officer, Director
  • David B. Johnston PhD, Chief Financial Officer, Executive Vice President
  • Ellie Harrison, Chief Human Resource Officer, Vice President
  • Richard J. Gregory Ph.D., Executive Vice President - Research, Chief Scientific Officer
  • John M. Lambert Ph.D., Executive Vice President - Distinguished Research Fellow
  • Craig Barrows, Vice President, General Counsel, Secretary
  • Peter J. Williams, Vice President - Business Development
  • Mark A. Goldberg M.D., Independent Director
  • Dean Jonathan Mitchell, Independent Director

Who owns ImmunoGen stock?

ImmunoGen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.29%), Russell Investments Group Ltd. (0.14%), Northeast Financial Consultants Inc (0.04%), Creative Planning (0.02%), Aperio Group LLC (0.02%) and US Bancorp DE (0.02%). Company insiders that own ImmunoGen stock include Charles Q Morris, Craig Barrows, Daniel M Junius, David Brannon Johnston, Dean J Mitchell, John Lambert, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.

Who sold ImmunoGen stock? Who is selling ImmunoGen stock?

ImmunoGen's stock was sold by a variety of institutional investors in the last quarter, including Creative Planning and US Bancorp DE. View Insider Buying and Selling for ImmunoGen.

Who bought ImmunoGen stock? Who is buying ImmunoGen stock?

ImmunoGen's stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Aperio Group LLC and Fisher Asset Management LLC. Company insiders that have bought ImmunoGen stock in the last two years include Craig Barrows, Dean J Mitchell, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.

How do I buy ImmunoGen stock?

Shares of ImmunoGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmunoGen's stock price today?

One share of ImmunoGen stock can currently be purchased for approximately $6.19.

MarketBeat Community Rating for ImmunoGen (NASDAQ IMGN)
Community Ranking:  2.5 out of 5 (  )
Outperform Votes:  212 (Vote Outperform)
Underperform Votes:  206 (Vote Underperform)
Total Votes:  418
MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ImmunoGen (NASDAQ:IMGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $6.61 (6.85% upside)

Analysts' Ratings History for ImmunoGen (NASDAQ:IMGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/6/2017Royal Bank Of CanadaUpgradeSector Perform -> Outperform$5.00 -> $12.00HighView Rating Details
6/28/2017Jefferies Group LLCReiterated RatingBuy$6.00HighView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
6/19/2017Leerink SwannReiterated RatingOutperform$8.00 -> $11.00HighView Rating Details
6/4/2017Cantor FitzgeraldSet Price TargetHold$5.00MediumView Rating Details
5/19/2017Canaccord GenuitySet Price TargetBuy$6.00LowView Rating Details
5/6/2017Cowen and CompanyReiterated RatingHoldHighView Rating Details
3/1/2017Morgan StanleyLower Price TargetUnderweight$2.50 -> $1.30N/AView Rating Details
8/5/2016J P Morgan Chase & CoSet Price TargetHold$9.00 -> $5.00N/AView Rating Details
11/10/2015Oppenheimer Holdings, Inc.Reiterated RatingBuy$24.00N/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for ImmunoGen (NASDAQ:IMGN)
Earnings by Quarter for ImmunoGen (NASDAQ:IMGN)
Earnings History by Quarter for ImmunoGen (NASDAQ IMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/20173/31/2017($0.36)($0.20)$16.16 million$28.70 millionViewN/AView Earnings Details
2/17/2017Q2 2017($0.39)($0.39)$16.28 million$13.85 millionViewListenView Earnings Details
10/28/2016Q117($0.38)($0.51)$21.12 million$7.66 millionViewListenView Earnings Details
8/4/2016Q416($0.39)($0.51)$17.11 million$7.41 millionViewListenView Earnings Details
4/29/2016Q316($0.31)($0.37)$23.02 million$19.71 millionViewListenView Earnings Details
1/29/2016Q216($0.36)($0.38)$19.54 million$18.03 millionViewListenView Earnings Details
10/27/2015Q116($0.35)($0.39)$15.84 million$14.90 millionViewListenView Earnings Details
7/31/2015Q415($0.34)($0.35)$15.42 million$12.61 millionViewListenView Earnings Details
4/24/2015Q315($0.25)($0.25)$20.95 million$11.40 millionViewListenView Earnings Details
1/30/2015Q215($0.06)$0.16$37.30 million$48.30 millionViewListenView Earnings Details
10/24/2014Q115($0.14)($0.26)$21.80 million$13.20 millionViewListenView Earnings Details
8/1/2014Q414($0.36)($0.31)$9.72 million$5.74 millionViewN/AView Earnings Details
4/25/2014Q314($0.27)($0.44)$13.28 million$6.90 millionViewN/AView Earnings Details
1/31/2014Q214($0.18)($0.29)$18.16 million$30.10 millionViewListenView Earnings Details
10/25/2013Q114($0.23)($0.13)$12.10 million$17.20 millionViewN/AView Earnings Details
8/2/2013Q4 2013($0.30)($0.26)$3.44 million$3.83 millionViewN/AView Earnings Details
4/26/2013Q3 2013($0.15)($0.02)$11.94 million$25.00 millionViewN/AView Earnings Details
1/25/2013Q2 2013($0.25)($0.29)$6.02 million$2.60 millionViewN/AView Earnings Details
10/26/2012Q113($0.25)($0.30)$4.10 million$4.10 millionViewN/AView Earnings Details
8/3/2012($0.30)($0.29)ViewN/AView Earnings Details
4/27/2012($0.26)($0.24)ViewN/AView Earnings Details
1/27/2012($0.22)($0.17)ViewN/AView Earnings Details
10/27/2011($0.22)($0.26)ViewN/AView Earnings Details
8/3/2011($0.24)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ImmunoGen (NASDAQ:IMGN)
2017 EPS Consensus Estimate: ($1.19)
2018 EPS Consensus Estimate: ($1.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.33)($0.33)($0.33)
Q2 20173($0.35)$0.17($0.07)
Q3 20173($0.46)($0.37)($0.41)
Q4 20172($0.40)($0.36)($0.38)
Q1 20181($0.41)($0.41)($0.41)
Q2 20181($0.37)($0.37)($0.37)
Q3 20181($0.37)($0.37)($0.37)
Q4 20181($0.38)($0.38)($0.38)
(Data provided by Zacks Investment Research)


Dividend History for ImmunoGen (NASDAQ:IMGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ImmunoGen (NASDAQ:IMGN)
Insider Ownership Percentage: 6.51%
Institutional Ownership Percentage: 73.91%
Insider Trades by Quarter for ImmunoGen (NASDAQ:IMGN)
Institutional Ownership by Quarter for ImmunoGen (NASDAQ:IMGN)
Insider Trades by Quarter for ImmunoGen (NASDAQ:IMGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2016Mark Alan GoldbergDirectorBuy20,000$1.80$36,000.00View SEC Filing  
11/8/2016Mark J EnyedyCEOBuy25,000$1.83$45,750.00View SEC Filing  
11/2/2016Craig BarrowsInsiderBuy10,000$1.71$17,100.00View SEC Filing  
11/2/2016Richard J GregoryVPBuy16,600$1.78$29,548.00View SEC Filing  
2/1/2016John LambertEVPSell3,889$8.22$31,967.58View SEC Filing  
1/8/2016Richard J GregoryVPSell2,369$11.10$26,295.90View SEC Filing  
1/4/2016Daniel M. JuniusCEOSell5,416$13.17$71,328.72View SEC Filing  
1/4/2016John LambertEVPSell3,889$13.20$51,334.80View SEC Filing  
12/1/2015Daniel M. JuniusCEOSell5,416$13.11$71,003.76View SEC Filing  
12/1/2015John LambertEVPSell3,889$13.11$50,984.79View SEC Filing  
11/27/2015Charles Q MorrisVPSell5,170$14.00$72,380.00View SEC Filing  
11/17/2015Dean J MitchellDirectorBuy10,000$12.51$125,100.00View SEC Filing  
11/2/2015Daniel M. JuniusCEOSell5,497$12.00$65,964.00View SEC Filing  
11/2/2015John LambertEVPSell3,889$11.73$45,617.97View SEC Filing  
10/29/2015Daniel M. JuniusCEOSell5,335$12.01$64,073.35View SEC Filing  
10/1/2015John LambertEVPSell3,889$9.55$37,139.95View SEC Filing  
9/17/2015David Brannon JohnstonCFOSell5,000$15.00$75,000.00View SEC Filing  
9/1/2015Daniel M. JuniusCEOSell5,416$13.15$71,220.40View SEC Filing  
9/1/2015John LambertEVPSell3,889$13.16$51,179.24View SEC Filing  
7/1/2015Daniel M JuniusCEOSell5,416$14.34$77,665.44View SEC Filing  
7/1/2015John LambertEVPSell3,888$14.34$55,753.92View SEC Filing  
6/15/2015Nicole OnettoDirectorSell3,211$13.86$44,504.46View SEC Filing  
6/1/2015John LambertEVPSell15,000$11.78$176,700.00View SEC Filing  
5/7/2015Daniel M JuniusCEOSell1,215$8.02$9,744.30View SEC Filing  
5/1/2015John LambertEVPSell10,000$8.32$83,200.00View SEC Filing  
11/28/2014Charles Q MorrisVPSell5,240$10.40$54,496.00View SEC Filing  
3/17/2014Daniel JuniusCEOSell15,000$16.40$246,000.00View SEC Filing  
2/26/2014Charles MorrisVPSell6,936$17.35$120,339.60View SEC Filing  
2/20/2014Charles MorrisVPSell13,672$17.10$233,791.20View SEC Filing  
2/18/2014Daniel JuniusCEOSell15,000$16.26$243,900.00View SEC Filing  
2/3/2014John LambertEVPSell4,375$14.90$65,187.50View SEC Filing  
1/22/2014Charles MorrisVPSell7,138$17.00$121,346.00View SEC Filing  
1/10/2014Theresa WingroveVPSell6,250$15.04$94,000.00View SEC Filing  
1/2/2014John LambertEVPSell4,375$14.53$63,568.75View SEC Filing  
12/10/2013Daniel JuniusCEOSell15,000$15.11$226,650.00View SEC Filing  
12/2/2013John LambertEVPSell4,375$14.70$64,312.50View SEC Filing  
11/26/2013Charles MorrisVPSell12,500$13.75$171,875.00View SEC Filing  
11/1/2013John LambertEVPSell4,375$16.41$71,793.75View SEC Filing  
9/10/2013Gregory D PerryCFOSell18,337$17.82$326,765.34View SEC Filing  
9/3/2013Daniel JuniusCEOSell16,667$16.43$273,838.81View SEC Filing  
9/3/2013John LambertEVPSell4,375$16.45$71,968.75View SEC Filing  
8/1/2013Daniel M JuniusCEOSell16,667$19.21$320,173.07View SEC Filing  
8/1/2013John LambertEVPSell4,375$19.21$84,043.75View SEC Filing  
7/11/2013James J O'learyVPSell35,000$19.02$665,700.00View SEC Filing  
7/3/2013Daniel M JuniusCEOSell16,667$17.31$288,505.77View SEC Filing  
7/1/2013John LambertEVPSell4,375$16.80$73,500.00View SEC Filing  
6/3/2013John LambertEVPSell11,250$17.20$193,500.00View SEC Filing  
5/24/2013James J O'learyVPSell28,900$18.11$523,379.00View SEC Filing  
5/1/2013John LambertEVPSell11,250$15.56$175,050.00View SEC Filing  
4/11/2013James J O'learyVPSell31,100$17.37$540,207.00View SEC Filing  
11/8/2012Mark Alan GoldbergDirectorBuy3,000$11.27$33,810.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ImmunoGen (NASDAQ:IMGN)
Latest Headlines for ImmunoGen (NASDAQ:IMGN)
DateHeadline logo$0.11 Earnings Per Share Expected for ImmunoGen, Inc. (IMGN) This Quarter - July 26 at 8:22 AM logoImmunoGen, Inc. breached its 50 day moving average in a Bearish Manner : IMGN-US : July 24, 2017 - July 26 at 1:08 AM logoWhy ImmunoGen, Inc. Jumped Higher Today -- The Motley Fool - Motley Fool - July 24 at 11:37 PM logoImmunoGen, Inc. (NASDAQ:IMGN) Cut to Buy at BidaskClub - July 23 at 4:58 PM logoIs a Beat in the Cards for ImmunoGen (IMGN) in Q2 Earnings? - July 21 at 4:23 PM logoImmunoGen, Inc. to Post Q2 2017 Earnings of $0.17 Per Share, Jefferies Group Forecasts (NASDAQ:IMGN) - July 21 at 8:26 AM logoQ2 2017 EPS Estimates for ImmunoGen, Inc. (IMGN) Increased by Analyst - July 20 at 8:07 AM logoImmunogen Finally Moving 'FORWARD'? - Seeking Alpha - July 19 at 8:55 PM logoImmunoGen, Inc. (IMGN) Given Consensus Rating of "Hold" by Analysts - July 18 at 10:34 PM logoImmunoGen Announces Conference Call to Discuss Its Second Quarter 2017 Financial Results - July 15 at 2:11 AM logoCan ImmunoGen's Lead Pipeline Cancer Candidate Boost Growth? - July 14 at 3:47 AM logoCan ImmunoGen's Lead Pipeline Cancer Candidate Boost Growth? - July 14 at 3:47 AM logoHere's Why ImmunoGen, Inc. Shares Exploded 54% Higher in June - July 10 at 7:47 PM logoZacks Investment Research Downgrades ImmunoGen, Inc. (NASDAQ:IMGN) to Sell - July 10 at 12:20 PM logoImmunoGen, Inc. (NASDAQ:IMGN) Lifted to "Outperform" at Royal Bank Of Canada - July 9 at 9:24 AM logoETFs with exposure to ImmunoGen, Inc. : July 7, 2017 - July 8 at 11:42 AM logoImmunoGen's Turnaround Is 'In Full-Swing' Following ASCO Presentations - July 6 at 11:43 AM logoImmunoGen, Inc. to Post Q3 2017 Earnings of ($0.46) Per Share, Jefferies Group Forecasts (NASDAQ:IMGN) - July 3 at 7:58 AM logoZacks: Brokerages Anticipate ImmunoGen, Inc. (IMGN) Will Post Quarterly Sales of $14.15 Million - July 2 at 10:44 AM logoImmunoGen - Reentry Puzzle - Seeking Alpha - July 1 at 1:00 AM logoImmunoGen, Inc. (IMGN) Expected to Post Earnings of -$0.40 Per Share - June 30 at 11:16 AM logoImmunogen (IMGN): Raising PT After Management Meetings - Jefferies - - June 30 at 5:14 AM logoImmunoGen's (IMGN) "Buy" Rating Reiterated at Jefferies Group LLC - June 28 at 11:28 AM logoResearch Analysts Offer Predictions for ImmunoGen, Inc.'s Q2 2017 Earnings (IMGN) - June 28 at 7:32 AM logoWhy ImmunoGen, Inc. Jumped Higher on Monday -- The Motley Fool - Motley Fool - June 27 at 6:04 PM
News IconBRIEF-ImmunoGen presents data from Phase I study of IMGN779 in acute myeloid leukemia - June 27 at 5:42 AM logoImmunogen (IMGN) Presents Data from Phase I Study of IMGN779 ... - - June 27 at 12:41 AM logoWhy ImmunoGen, Inc. Jumped Higher on Monday - June 26 at 9:23 PM logoETFs with exposure to ImmunoGen, Inc. : June 26, 2017 - June 26 at 7:40 PM logoImmunogen (IMGN) Presents Data from Phase I Study of IMGN779 in AML - June 26 at 9:25 AM logoImmunoGen Presents Data from Phase I Study of IMGN779 in Acute Myeloid Leukemia - June 26 at 9:25 AM logoImmunoGen, Inc. (IMGN) Earns "Outperform" Rating from William Blair - June 26 at 8:34 AM logoImmunoGen, Inc. (IMGN) Expected to Earn FY2017 Earnings of ($1.50) Per Share - June 26 at 7:41 AM logo5 Best Biotech Stocks of 2017 So Far - June 25 at 2:04 PM logoHead-To-Head Survey: Concert Pharmaceuticals (CNCE) & ImmunoGen (IMGN) - June 24 at 12:14 PM logoImmunoGen, Inc. (IMGN) Receives Consensus Recommendation of "Hold" from Analysts - June 23 at 8:36 PM logoWhy ImmunoGen, Inc. Jumped Higher for the Second Day in a Row - June 22 at 10:46 PM logoWhy ImmunoGen, Inc. Jumped Higher for the Second Day in a Row - Motley Fool - June 22 at 1:15 PM logoImmunoGen, Inc. (IMGN) Upgraded by ValuEngine to "Hold" - June 21 at 10:02 PM logoBiopharma Stock Breakouts With Significant Developments and Market Activity - June 21 at 3:35 PM logoImmunoGen (IMGN) Jumps: Stock Rises 10.4% - June 21 at 3:34 PM logoTwo Bullish Biotech Stocks And A Very Bearish Looking Yelp - June 21 at 3:34 PM logoImmunoGen Stock Nears Breakout to New Highs (IMGN) - June 20 at 6:45 PM logoImmunoGen Stock Nears Breakout to New Highs - June 20 at 6:45 PM logoImmunoGen's (IMGN) Outperform Rating Reiterated at Leerink Swann - June 19 at 8:16 PM logoETFs with exposure to ImmunoGen, Inc. : June 16, 2017 - June 16 at 6:45 PM logoWhy Is ImmunoGen (IMGN) Stock Up 131% This Year? - June 16 at 5:07 AM logoImmunoGen, Inc. :IMGN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 - June 14 at 11:26 AM logoImmunoGen (IMGN) Up 21.2% Since Earnings Report: Can It Continue? - Nasdaq - June 7 at 10:09 AM logoImmunoGen (IMGN) Up 21.2% Since Earnings Report: Can It Continue? - June 7 at 10:09 AM



ImmunoGen (IMGN) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff